Memo Therapeutics

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company’s antibody discovery platform utilizes powerful, simple, and rapid microfluidic single-cell molecular cloning and screening technology to mine antibody libraries and discover antibodies with unprecedented speed, efficiency, and sensitivity. The platform captures and preserves complete B-cell repertoires from any donor species and any B-cell type in recombinant form for use with mammalian cell display. Subsequently, microfluidic screening technology is employed to screen antibody libraries at the single-cell level, allowing direct assessment of millions of candidate antibodies in functional assays, resulting in recombinant clonal cell lines expressing monoclonal antibodies (mAbs) with desired functional properties. Leveraging the capabilities of its microfluidic single-cell molecular cloning and screening technology, Memo Therapeutics AG focuses on cross-species antibody discovery as well as proprietary and collaborative projects across various indications. The company’s current pipeline includes programs in infectious diseases and immuno-oncology. Memo Therapeutics AG is a private company located in the Zurich Biotech Park in Switzerland.